Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06665542

A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.

The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.

The study will recruit patients presenting with suspicion of acute infection/sepsis and healthy individuals.

Study main objective is to derive and verify a host response based score to predicte severe outcome.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Carmel MC, Haifa, Israel

Loading trial locations.

About this study

For determining disease severity each enrolled patient will be assigned as either "severe outcome patient" or "non severe outcome patient" according to predefined criteria. (or "healthy").

Participation in the study requires the collection of routine patient data and blood sample. Blood samples will be used for measurements of host biomarkers that predict disease severity. The blood samples will be collected upon enrollment.

In addition, a standardized patient questionnaire inquiring about severity outcomes met up to 28 days after presentation will be conducted by phone call 28 to 42 days post admission.

Enrolled patients will be managed according to the current standard of care per standard institutional procedures. Results of the measured biomarkers will not be revealed to the attending clinician and so will not influence patient management.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Suspected acute infection/sepsis patients

Patients eligible for inclusion are required to fulfill all of the following criteria:

  • Written informed consent must be obtained from the patient or his/her legal guardian.
  • Over 18 years of age
  • Clinical suspicion of acute infection/sepsis as defined by the attending physician, based on clinical presentation.

Healthy individuals

Patients eligible for inclusion are required to fulfill all of the following criteria:

  • Written informed consent must be obtained from the patient
  • Over 18 years of age
  • No clinical suspicion of acute infection.

Exclusion criteria

Suspected acute infection/sepsis patients

Patients fulfilling the following criteria are not eligible for inclusion in this study:

  • HIV, HBV, active HCV or active Tuberculosis infection (self-declared or known from medical records).
  • Pregnancy- self reported or medically confirmed. Healthy individuals

Patients fulfilling the following criteria are not eligible for inclusion in this study:

  • Episode of infection in the last 2 weeks
  • Major trauma and\\or burns and\\or surgery in the last 2 weeks
  • HIV, HBV, active HCV or active Tuberculosis infection (self-declared or known from medical records)
  • Elective surgery patients
  • Pregnancy- self reported or medically confirmed

Treatment and study plan

Primary outcomes

  1. Primary objective

    Time frame: 3,14 and 28 Days

    To derive and verify the diagnostic performance of a host-response tool based on novel biomarkers for predicting disease severity in adult patients, aged 18 years or older, presenting with clinical suspicion of acute infection/sepsis.

Sponsors and collaborators

Lead sponsor

MeMed Diagnostics Ltd.

Industry

Registry information

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Oct 30, 2024
Registry last updated
Oct 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.